Highlights 

  • CollPlant advances rhCollagen programs and expands North American distribution 
  • Mayo Clinic develops first humanized bioprinted skin model using CollPlant’s rhCollagen 
  • Collink.3D™ bioink outperforms Matrigel® in key comparative study 
  • Cost-reduction plan and program prioritization expected to extend cash runway 
  • AbbVie collaboration progresses as lead dermal filler candidate moves through clinical evaluation 

CollPlant Biotechnologies (NASDAQ:CLGN) reported its third-quarter 2025 financial results, highlighting scientific progress, commercial expansion and ongoing program development. The company’s proprietary non-animal recombinant human collagen (rhCollagen) continues to gain recognition as an ethical, sustainable and high-performance alternative for use across tissue engineering, aesthetics and advanced preclinical research. 

A key milestone this quarter came from the Mayo Clinic, where researchers created the first fully humanized 3D bioprinted skin model using CollPlant’s rhCollagen. This model provides an alternative to animal testing for pharmaceutical, cosmetic, and dermatology research. Additionally, a comparative study from Technion demonstrated that Collink.3D™, CollPlant’s rhCollagen-based bioink, surpassed Matrigel® in supporting structured tissue formation—an opportunity representing a market estimated at USD 100 million with annual growth of over 10%. 

These findings underscore increasing demand for consistent and animal-free biomaterials across drug discovery, regenerative medicine, and tissue modeling. 

Progress in Aesthetic Programs and AbbVie Collaboration 

CollPlant continues to advance its photocurable dermal filler candidate, now in the final stages of preclinical evaluation. The product aims to combine facial contouring precision with regenerative potential in a single injectable. Production scale-up is underway as the company prepares for clinical studies. 

Meanwhile, the landmark 2021 commercialization partnership with Allergan/AbbVie continues to move forward. AbbVie provided a USD 2 million milestone payment earlier this year after achieving a key development goal. AbbVie is currently reviewing interim data from the lead dermal filler candidate’s clinical program, having enrolled its first cohort of patients. Upcoming steps for the collaboration will be determined following AbbVie’s assessment. 

To streamline operations and extend the cash runway, CollPlant initiated a cost-reduction plan including a workforce reduction of approximately 25%. CEO Yehiel Tal has also been nominated as interim Chairman following the planned departure of current Chairman Dr. Roger Pomerantz. 

Commercial Expansion and Financial Performance 

CollPlant announced a new U.S.-based logistics partnership that will become operational this quarter, providing cGMP-compliant distribution for rhCollagen and BioInk products across North America. The company is also expanding internationally, broadening access to its Vergenix™ STR tendon-repair product into seven new markets in Europe and Asia. 

Financially, Q3 2025 GAAP revenue reached USD 77,000, up from USD 4,000 in the same period last year, driven by higher rhCollagen product sales. For the nine-month period,revenuetotaled USD 2.3 million, increased by the AbbVie milestone.Operating expensesdecreased due to cost-cutting initiatives, and net loss narrowed to USD 3.5 million for the quarter.Cash and cash equivalentsstood at USD 8.5 million as of September 30, 2025. 

Conclusion 

CollPlant enters the final quarter of 2025 with accelerating scientific validation, expanding commercial reach and continued progress in both internal and partnered aesthetic programs. The growing adoption of rhCollagen in human-based research and regenerative applications highlights the company’s position in an evolving market that increasingly values ethical and consistent biomaterials.